← Back to Search

Cannabinoid

CBD on Brain Function (CBD Trial)

N/A

Waitlist Available

Led By Jennifer L Robinson, Ph.D.

Research Sponsored by Auburn University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up collected pre-drug, post-drug, pre-placebo, and post-placebo; through study completion (4 time points over a 72 hour period)

Awards & highlights

CBD Trial Summary

This trial will examine the acute effects of CBD on the brain. 100% THC-free CBD will be compared to placebo, and participants will be scanned before and after ingestion. Results will help to determine if CBD has any neurometabolic or neurophysiological effects, and if it affects working memory or response inhibition.

Who is the study for?

This trial is for right-handed adults aged 21-50 who are generally healthy, with no psychiatric or neurological conditions, heart disease, stroke history, or contraindications to MRI scans. Participants must not consume certain substances before scans and cannot be on psychotropic or neurological medications.Check my eligibility

What is being tested?

The study tests the effects of THC-free Cannabidiol (CBD) versus a placebo on brain function and behavior. It's a double-blind study where participants take CBD capsules and undergo pre- and post-ingestion brain scans in two sessions separated by a washout period.See study design

What are the potential side effects?

While CBD is generally considered safe and non-addictive, potential side effects may include changes in alertness, gastrointestinal discomfort, mood swings, drowsiness, dry mouth, or low blood pressure.

CBD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ collected pre-drug, post-drug, pre-placebo, and post-placebo; through study completion (4 time points over a 72 hour period)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~collected pre-drug, post-drug, pre-placebo, and post-placebo; through study completion (4 time points over a 72 hour period)

This trial's timeline: 3 weeks for screening, Varies for treatment, and collected pre-drug, post-drug, pre-placebo, and post-placebo; through study completion (4 time points over a 72 hour period) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

BOLD - Change in Threat Response to Subliminal Emotion Stimuli

Behavioral Measures - Change in Go/No-Go Accuracy

Behavioral Measures - Change in Go/NoGo Reaction Time

+5 more

Side effects data

From 2022 Phase 2 & 3 trial • 90 Patients • NCT04387617

38%

Tiredness

24%

Drowsiness

24%

Poor sleep

22%

Constipation

18%

Poor Appetite

16%

Dizziness

Headache

Diarrhea

Nausea

Itching

100%

80%

60%

40%

20%

Study treatment Arm

CBD Oil Group

Control Group

CBD Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Cannabidiol (CBD)Experimental Treatment2 Interventions

A tincture containing 125mg broad spectrum CBD oil (6.7%), 24mg sunflower lecithin (1.3%), 56mg peppermint oil (3.0%), and 1661mg hempseed oil (89.0%) will be administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.

Group II: PlaceboPlacebo Group2 Interventions

A tincture containing 149mg sunflower lecithin (8.0%), 56mg peppermint oil (3.0%), 1661mg hempseed oil (89.0%) will be administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Placebo

1995

Completed Phase 3

~2670

Cannabidiol

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Folium BiosciencesUNKNOWN

Auburn UniversityLead Sponsor

72 Previous Clinical Trials

14,390 Total Patients Enrolled

FutureCeuticalsUNKNOWN

Media Library

Cannabidiol (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04831294 — N/A

Cannabidiol Research Study Groups: Placebo, Cannabidiol (CBD)

Cannabidiol Clinical Trial 2023: Cannabidiol Highlights & Side Effects. Trial Name: NCT04831294 — N/A

Cannabidiol (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04831294 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still availability for this clinical endeavor?

"According to the information posted on clinicaltrials.gov, this trial is actively seeking enrollees. It was initially created on July 15th 2021 and most recently updated September 22nd of this year."

Answered by AI

What is the size of the patient cohort for this research endeavor?

"Affirmative. Information posted on clinicaltrials.gov marks this study as actively recruiting candidates; the trial was first advertised on July 15th 2021 and has been up to date since September 22nd 2021. Fifteen people are needed for the single participating site."

Answered by AI

Are there any other research projects exploring the potential of Cannabidiol?

"At present, 79 trials are ongoing concerning Cannabidiol with 16 Phase 3 studies. Although some of the tests focus on Ribeirao Preto in Sao Paulo, there is a global presence as 290 sites worldwide have been assigned to run assessments for this drug."

Answered by AI

Is the research study accepting seniors as participants?

"According to the inclusion criteria, only individuals between 21 and 50 can partake in this clinical trial. There are 22 studies available for minors under 18 years of age, as well as 62 trials designed specifically for seniors over 65."

Answered by AI

Who would benefit most from participating in this medical experiment?

"This experiment is currently recruiting 15 individuals between 21 and 50 years of age who do not possess a history of cardiac or neurological ailments, nor any psychiatric diagnosis."

Answered by AI